{"id":54879,"date":"2026-01-20T20:21:30","date_gmt":"2026-01-20T12:21:30","guid":{"rendered":"https:\/\/flcube.com\/?p=54879"},"modified":"2026-01-20T20:21:32","modified_gmt":"2026-01-20T12:21:32","slug":"d3-bios-kras-programs-advance-fda-clears-phase-i-g12d-inhibitor-d3s-003-and-phase-ii-g12c-erk-combo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54879","title":{"rendered":"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo"},"content":{"rendered":"\n<p><strong>D3 Bio<\/strong> announced FDA clearance for two clinical programs: a <strong>Phase\u202fI first\u2011in\u2011human study for D3S\u2011003<\/strong>, an <strong>oral allele\u2011specific KRAS\u202fG12D inhibitor<\/strong>, and a <strong>Phase\u202fII trial for the combination of D3S\u2011001 (KRAS\u202fG12C inhibitor) plus D3S\u2011002 (ERK1\/2 inhibitor)<\/strong> in <strong>KRAS\u202fG12C\u2011mutated NSCLC<\/strong>, positioning the company at the forefront of <strong>next\u2011generation KRAS\u2011targeted oncology<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>D3 Bio (private)<\/td><\/tr><tr><td>**Programs<\/td><td>D3S\u2011003 (KRAS\u202fG12D inhibitor) &amp; D3S\u2011001 + D3S\u2011002 combo (KRAS\u202fG12C + ERK1\/2)<\/td><\/tr><tr><td>**FDA Approvals<\/td><td>Phase\u202fI for D3S\u2011003; Phase\u202fII for D3S\u2011001 + D3S\u2011002<\/td><\/tr><tr><td>**Indications<\/td><td>Advanced solid tumors (G12D) &amp; KRAS\u202fG12C NSCLC (combo)<\/td><\/tr><tr><td>**Study Start<\/td><td>H1\u202f2026 (both programs)<\/td><\/tr><tr><td>**Innovation<\/td><td>First G12D inhibitor targeting both OFF\/ON conformations; CNS\u2011penetrant G12C inhibitor with ERK1\/2 resistance\u2011breaker<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profiles-amp-mechanism-of-action\">Drug Profiles &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-d3s-003-kras-g12d-inhibitor\">D3S\u2011003 (KRAS\u202fG12D Inhibitor)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Oral, <strong>allele\u2011specific<\/strong>, binds <strong>GDP\u2011bound (OFF) and GTP\u2011bound (ON)<\/strong> KRAS\u202fG12D conformations<\/li>\n\n\n\n<li><strong>Preclinical:<\/strong> Potent antitumor activity, favorable drug\u2011like properties, promising safety window<\/li>\n\n\n\n<li><strong>Clinical Plan:<\/strong> Phase\u202fI dose\u2011escalation in <strong>advanced solid tumors harboring G12D mutations<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-d3s-001-elisrasib-kras-g12c-inhibitor\">D3S\u2011001 (Elisrasib, KRAS\u202fG12C Inhibitor)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Next\u2011gen G12C inhibitor with <strong>rapid, robust, selective target engagement<\/strong> and <strong>CNS penetration<\/strong><\/li>\n\n\n\n<li><strong>Preclinical:<\/strong> Achieves <strong>complete KRAS\u202fG12C occupancy<\/strong> at clinically relevant exposures<\/li>\n\n\n\n<li><strong>Clinical Plan:<\/strong> Phase\u202fII combo trial with <strong>D3S\u2011002 (ERK1\/2 inhibitor)<\/strong> in <strong>KRAS\u202fG12C NSCLC<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-d3s-002-erk1-2-inhibitor\">D3S\u2011002 (ERK1\/2 Inhibitor)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Selective ERK1\/2 inhibitor designed to <strong>overcome acquired resistance<\/strong> to KRAS\u202fG12C inhibitors<\/li>\n\n\n\n<li><strong>Synergy:<\/strong> Blocks downstream signaling, prevents tumor escape<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program<\/th><th>Target<\/th><th>Addressable Population (2030E)<\/th><th>Market Value (2030E)<\/th><th>Key Competitors<\/th><\/tr><\/thead><tbody><tr><td><strong>D3S\u2011003<\/strong><\/td><td>KRAS\u202fG12D (pan\u2011solid tumor)<\/td><td>180,000 (China), 900,000 (global)<\/td><td>\u00a512\u202fB \/ $7.5\u202fB<\/td><td>Mirati\u2019s MRTX1133 (Phase\u202fI), Revolution Medicines (pre\u2011clinical)<\/td><\/tr><tr><td><strong>D3S\u2011001 + D3S\u2011002<\/strong><\/td><td>KRAS\u202fG12C NSCLC (post\u20111L)<\/td><td>42,000 (China), 95,000 (global)<\/td><td>\u00a58\u202fB \/ $5.2\u202fB<\/td><td>Mirati adagrasib, Amgen sotorasib, Roche divarasib (all monotherapy)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Differentiation:<\/strong> D3S\u2011003\u2019s <strong>dual\u2011conformation targeting<\/strong> vs. competitors\u2019 OFF\u2011only inhibitors; combo\u2019s <strong>ERK1\/2 resistance\u2011breaker<\/strong> vs. single\u2011agent G12C inhibitors<\/li>\n\n\n\n<li><strong>CNS Penetration:<\/strong> D3S\u2011001\u2019s ability to cross blood\u2011brain barrier offers <strong>advantage in brain metastases<\/strong>, a key unmet need<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> D3 Bio\u2019s <strong>Shanghai facility<\/strong> (robotic synthesis) will supply both programs; <strong>scale\u2011up to 10,000 doses<\/strong> by 2027<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> Rapid Phase\u202fI readout for D3S\u2011003 expected <strong>Q4\u202f2026<\/strong>; combo Phase\u202fII topline <strong>Q2\u202f2027<\/strong><\/li>\n\n\n\n<li><strong>Global Licensing:<\/strong> D3 Bio plans <strong>ex\u2011China partnerships<\/strong> post\u2011Phase\u202fI for D3S\u2011003 and post\u2011Phase\u202fII for combo; <strong>potential deal value $800M\u20111.2B<\/strong><\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Success validates <strong>next\u2011gen KRAS platform<\/strong>, supporting <strong>earlier\u2011stage assets<\/strong> (D3S\u2011004, D3S\u2011005)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for D3S\u2011003 and the D3S\u2011001 + D3S\u2011002 combo. Actual results may differ due to competitive responses, clinical trial outcomes, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>D3 Bio announced FDA clearance for two clinical programs: a Phase\u202fI first\u2011in\u2011human study for D3S\u2011003,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1122],"class_list":["post-54879","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-d3-bio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"D3 Bio announced FDA clearance for two clinical programs: a Phase\u202fI first\u2011in\u2011human study for D3S\u2011003, an oral allele\u2011specific KRAS\u202fG12D inhibitor, and a Phase\u202fII trial for the combination of D3S\u2011001 (KRAS\u202fG12C inhibitor) plus D3S\u2011002 (ERK1\/2 inhibitor) in KRAS\u202fG12C\u2011mutated NSCLC, positioning the company at the forefront of next\u2011generation KRAS\u2011targeted oncology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54879\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo\" \/>\n<meta property=\"og:description\" content=\"D3 Bio announced FDA clearance for two clinical programs: a Phase\u202fI first\u2011in\u2011human study for D3S\u2011003, an oral allele\u2011specific KRAS\u202fG12D inhibitor, and a Phase\u202fII trial for the combination of D3S\u2011001 (KRAS\u202fG12C inhibitor) plus D3S\u2011002 (ERK1\/2 inhibitor) in KRAS\u202fG12C\u2011mutated NSCLC, positioning the company at the forefront of next\u2011generation KRAS\u2011targeted oncology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54879\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T12:21:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T12:21:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54879#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54879\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo\",\"datePublished\":\"2026-01-20T12:21:30+00:00\",\"dateModified\":\"2026-01-20T12:21:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54879\"},\"wordCount\":514,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"D3 Bio\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54879#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54879\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54879\",\"name\":\"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-20T12:21:30+00:00\",\"dateModified\":\"2026-01-20T12:21:32+00:00\",\"description\":\"D3 Bio announced FDA clearance for two clinical programs: a Phase\u202fI first\u2011in\u2011human study for D3S\u2011003, an oral allele\u2011specific KRAS\u202fG12D inhibitor, and a Phase\u202fII trial for the combination of D3S\u2011001 (KRAS\u202fG12C inhibitor) plus D3S\u2011002 (ERK1\\\/2 inhibitor) in KRAS\u202fG12C\u2011mutated NSCLC, positioning the company at the forefront of next\u2011generation KRAS\u2011targeted oncology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54879#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54879\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54879#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo - Insight, China&#039;s Pharmaceutical Industry","description":"D3 Bio announced FDA clearance for two clinical programs: a Phase\u202fI first\u2011in\u2011human study for D3S\u2011003, an oral allele\u2011specific KRAS\u202fG12D inhibitor, and a Phase\u202fII trial for the combination of D3S\u2011001 (KRAS\u202fG12C inhibitor) plus D3S\u2011002 (ERK1\/2 inhibitor) in KRAS\u202fG12C\u2011mutated NSCLC, positioning the company at the forefront of next\u2011generation KRAS\u2011targeted oncology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54879","og_locale":"en_US","og_type":"article","og_title":"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo","og_description":"D3 Bio announced FDA clearance for two clinical programs: a Phase\u202fI first\u2011in\u2011human study for D3S\u2011003, an oral allele\u2011specific KRAS\u202fG12D inhibitor, and a Phase\u202fII trial for the combination of D3S\u2011001 (KRAS\u202fG12C inhibitor) plus D3S\u2011002 (ERK1\/2 inhibitor) in KRAS\u202fG12C\u2011mutated NSCLC, positioning the company at the forefront of next\u2011generation KRAS\u2011targeted oncology.","og_url":"https:\/\/flcube.com\/?p=54879","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-20T12:21:30+00:00","article_modified_time":"2026-01-20T12:21:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54879#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54879"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo","datePublished":"2026-01-20T12:21:30+00:00","dateModified":"2026-01-20T12:21:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54879"},"wordCount":514,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","D3 Bio"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54879#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54879","url":"https:\/\/flcube.com\/?p=54879","name":"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-20T12:21:30+00:00","dateModified":"2026-01-20T12:21:32+00:00","description":"D3 Bio announced FDA clearance for two clinical programs: a Phase\u202fI first\u2011in\u2011human study for D3S\u2011003, an oral allele\u2011specific KRAS\u202fG12D inhibitor, and a Phase\u202fII trial for the combination of D3S\u2011001 (KRAS\u202fG12C inhibitor) plus D3S\u2011002 (ERK1\/2 inhibitor) in KRAS\u202fG12C\u2011mutated NSCLC, positioning the company at the forefront of next\u2011generation KRAS\u2011targeted oncology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54879#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54879"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54879#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"D3 Bio\u2019s KRAS Programs Advance: FDA Clears Phase\u202fI G12D Inhibitor D3S\u2011003 and Phase\u202fII G12C\u2011ERK Combo"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54879"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54879\/revisions"}],"predecessor-version":[{"id":54880,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54879\/revisions\/54880"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}